A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-16673-304)

Principal Investigator

Dr Danmei Xu

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1012516